Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DENDR-STEM: GSC-loaded Dendritic Cells for Recurrent Glioblastoma
NCT02820584Phase 1Completed
- Sponsor
- Carlo Besta Neurological Institute
- Start
- Sep 2016
- Primary completion
- Jun 2017
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
01
Overview
Phase 1, open-label trial of GSC-DCV in glioblastoma (GBM), sponsored by Carlo Besta Neurological Institute. Primary endpoint: Adverse Events at 18 months. Started Sep 2016; status: completed.
02
Drugs
GSC-DCV
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02820584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02820584.